Corcept Therapeutics shares fell 20.1% on Friday, 23 October. No company announcement, filing or attributed report identified a cause by publication. The broader pharmaceutical preparations group also declined, with a median fall of 1.0%, while the S&P 500 fell 0.5%.
The fall was unusually large
The fall was 4.0 times a typical daily move for Corcept over the past year, when the standard deviation of daily returns was 5.1%. It was the largest fall of this size or greater since 31 December 2025. Trading volume was 2.1 times its 30-day average.
| Measure | Reading |
|---|---|
| Corcept share move | −20.1% |
| Typical daily move over the past year | 5.1% |
| Volume relative to 30-day average | 2.0579× |
| S&P 500 move in the session | −0.5% |
| Covered pharmaceutical preparations median move | −1.0% |
Recent filings show mixed financial trends
No available filing or report confirms a reason for the share decline. Recent company fundamentals provide context, but they do not establish why the shares fell that day.
Through FY2026 Q2, trailing-twelve-month revenue growth was 16.0%, up 3.8 percentage points from the prior quarter. Cash generation was weaker: free cash flow fell 40.8% year over year, while the FCF margin stood at 12.9%. Operating margin was 0.8%.
Revenue growth rose by 3.8 percentage points to 16.0%, while cash flow and margins were under pressure. Those trends matter to an assessment of Corcept’s financial performance, but there is no evidence tying them to the session’s share move.
The valuation model is sensitive to cash generation
The move leaves the shares at $85.86, compared with Fundamentalytics’ base-case model value of $46.00 per share. The latter is a model output based on stated assumptions, not a current market quote or an explanation for the fall.
The model is sensitive to cash generation. If the past year’s FCF-margin decline persists, the model’s value changes by −47.0%. A 1.0 percentage point lower FCF margin corresponds to a −7.2% model-value change. For comparison, a 5.0 percentage point reduction in growth corresponds to −22.4%, and a 1.0 percentage point increase in the discount rate corresponds to −14.5%. The model therefore assigns substantial weight to the durability of margins alongside growth assumptions. These are model values under stated assumptions, not a comparison with the share price.
The next results are scheduled for 4 November
Corcept’s next results are scheduled for 4 November 2026. Those results may provide updated information on revenue, margins and cash generation. Until a company statement, filing or attributable report explains the 23 October session, the reason for the fall remains unconfirmed.